Submission for OMB Review; Comment Request; ''Alcoholism Prevalence and Gene/Environment Interactions in Native American Tribes (a 10 Tribe Study)'' and ''A Native American Tribe With Low Alcoholism Prevalence: Transmission Analysis, Linkage Analysis and Gene/Environment Interactions (a) 1 Tribe Study)''

SUMMARY: Under the provisions of Section 3506(C)(2)(a) of the Paperwork Reduction Act of 1995, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously in the Federal Register on July 1, 1996, and allowed 60 days for public comment. There were no requests for additional information about this data collection activity, no public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The NIH may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after June 30, 1999, unless it displays a currently valid OMB control number.

Proposed Collection

Title: ''Alcoholism Prevalence and Gene/Environment Interactions in Native American Tribes (a 10 tribe study)'' and ''A Native American Tribe with Low Alcoholism Prevalence: Transmission Analysis, Linkage Analysis and Gene/Environment Interactions (a 1 tribe study)''. Type of Information Collection request: NEW. Need and Use of Information Collection: The information proposed for collection in both studies will be used by the NIAAA to define the prevalence in alcoholism and associated problems in tribes in which the rates of alcoholism have been reported to be widely divergent. Additional information will be collected on severe trauma and stress, alcohol availability and socioeconomic factors to identify how these variables interact with hereditary factors in the development of alcoholism and related problems.

Frequency of Response: On Occasion. Affected Public: Individuals. Type of Respondents: Native American adults. Estimated Number of Respondents: 1100. Estimated Number of Responses per Respondent: 1. Average Burden Hours per Response: 6. And Estimated Total Annual Burden Hours Requested: 6600. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

The annual burden estimates are as follows:

Type and number of respondents	Responses per respondent	Total responses	Hours	Total hours
Clients: 1,100	1	1,100	6.0	6,600

Total Number of Respondents: 3,300 (1,100 per year).

Total Number of Responses: 3,300 (1,100 per year).

Total Hours: 19,800 (6,600 per year).

Request for Comments

Comments are invited on: (a) Whether the proposed collection is necessary, including whether the information has practical use; (b) ways to enhance the clarity, quality, and use of the information to be collected; (c) the accuracy of the agency estimate of burden of the proposed collection; and (d) ways to minimize the collection burden of the respondents. Send written comments to Ms. Ronni Nelson, Laboratory of Neurogenetics, Division of Intramural Clinical and Biological Research, NIAAA, NIH, DANAC4 (Flow Labs), 12501 Washington Ave., Rockville, Maryland 20852.

Direct Comments to OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time should be directed to the Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans, contact Ms. Ronni Nelson, Laboratory of Neurogenetics, Division of Intramural Clinical and Biological Research (DICBR), NIAAA, DANAC4 (Flow Labs), 12501 Washington Ave., Rockville, Maryland 20852, or call non-toll-free number (301) 443–5781.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before April 16, 1997.

Dated: March 10, 1997.

Martin K. Trusty,

Executive Officer, NIAAA.

[FR Doc. 97–6637 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute

SUMMARY: The National Institutes of Health is seeking Cooperative Research and Development Agreement (CRADA) partners for the future development and commercialization of Active Transglutaminase I.

To speed the research and development of this compound, the National Institutes of Health is seeking a CRADA partner, in accordance with the Federal Technology Transfer Act of 1986, 15 U.S.C. 3710(a)(b), with capabilities to produce high grade quantities of the enzyme for further characterization and research in accordance with the regulations governing the transfer of Government-developed agents. Any proposals to produce and develop active Transglutaminase I will be considered.

ADDRESSES: CRADA proposals and questions about this opportunity should be addressed to: Ms. Sue Patow, Technology Transfer, NHLBI, Building 31, Room 1B30, Bethesda, MD 20892 (301–402–5579) or E-mail proposals and questions to: <PatowS@nih. gov>.

SUPPLEMENTARY INFORMATION: A supply of active human transflutaminase I enzyme (TG1) for therapeutic research is required. For this purpose a suitable protein expression system should be available (mammalian, insect or microorganism) which will utilize DNA we provide that codes for TG1. production of 5 mg or more TG1 protein may be required for sufficient enzyme activity, but the exact quantity and frequency of supply will depend on the stability and activity of the product. Minimally purified TG1 enzyme will be accepted for initial tests, but more purified enzyme may subsequently be required. The exact form of the TG1 enzyme to be supplied will depend on

the capabilities of the expression system. Synthesis of 'native' full-size enzyme (92 kDa) will have highest priority. Alternatively, a truncated TG1 with high activity and stability may be tested (65 kDa). A standard transglutaminase activity assay will be used by the contractor to determine TG1 activity, and assess stability and optimal storage conditions.

This CRADA aims include the rapid development of a supply of active human Transglutaminase I enzyme for further characterization and research, publication of research results and possible exploitation of commercial opportunities. The CRADA partner(s) will enjoy rights of first negotiation for licensing Government rights to any inventions arising under the agreement.

The role of the NIAMS in this CRADA will be as follows:

(1) Provide the Collaborator(s) with samples of the clone gene DNA;

(2) Perform initial tests on Collaborator produced test enzyme for activity and function; and

(3) Provide expertise in optimizing commercial development of this compound to produce the most useful product.

The role of the Collaborator will be as follows:

(1) Produce high quality Transglutaminase I in sufficient quantities for research studies;

(2) Perform initial testing of Transglutaminase I for purity; and

(3) Develop method(s) to produce large quantities of Transglutaminase I for commercial distribution.

Selection criteria for choosing the CRADA partner(s) will include but not be limited to:

(1) Ability to produce high quality Transglutaminase I in large quantities for research and evaluation;

(2) The level of financial support the Collaborator will supply for the CRADA related Government activities;

(3) A willingness to cooperate with the NIAMS in the publication of research results;

(4) An agreement to be bound by DHHS rules involving human subjects, patent rights, and ethical treatment of animals; and

(5) Agreement with provisions for equitable distribution of patent rights to any inventions developed under the CRADA(s).

Generally, the rights of ownership are retained by the organization which is the employer of the inventor with, (1) an irrevocable, non-exclusive, royalty-free license to the Government (when a company employee is sole inventor) or (2) an option to negotiate an exclusive or non-exclusive license to the company on terms that are appropriate (when the Government employee is the sole inventor).

Dated: March 4, 1997.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 97–6634 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings.

Name of SEP: Modeling DNA Diversity in Cardiovascular Health/Disease.

Date: March 26–27, 1997.

Time: 7:30 p.m.

Place: Holiday Inn, Gaithersburg, #2 Montgomery Village Avenue, Gaithersburg, Maryland 20879.

Contact Person: Anthony M. Coelho, Jr., Ph.D., Two Rockledge Center, Room 7194, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0299.

Purpose/Agenda: To review and evaluate grant applications.

This notice is being published less than fifteen days prior to this meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of SEP: Homocyst(E)inemia and Atherosclerosis.

Date: April 10–11, 1997.

Time: 8:00 p.m.

Place: Ramada, 1775 Rockville Pike, Rockville, Maryland 20852.

Contact Person: Eric H. Brown, Ph.D., Two Rockledge Center, Room 7204, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0299.

Purpose/Agenda: To review and evaluate grant applications.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6630 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following advisory committee meeting of the National Institute of General Medical Sciences:

Committee Name: Biomedical Research & Research Training Subcommittee-A.

Date: March 12, 1997.

Time: 8:00 a.m. until 6:00 p.m.

Place: Bethesda Holiday Inn, 8120 Wisconsin Avenue, Pennsylvania Room, Bethesda, Maryland 20814.

Contact Person: Carole H. Latker, Ph.D., Office of Scientific Review, Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS–19G, Bethesda, MD 20892–6200, 301–594–2848.

Purpose: To review institutional research training grant applications.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and the discussions of these could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.821, Biophysics and Physiological Sciences: 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: March 12, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6626 Filed 3–14–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: Gene Therapy for Epidermolysis Bullosa.

Date: April 4, 1997.

Time: 8:30 a.m.–adjournment.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.